#### Values presented in table
* Strategy and Case 
* drug development planning chararcteristics: assumed true hazard rate (HR), event rates for phase II and III (&xi;<sub>i</sub>, i=2,3)
* expected utility (u)
* threshold value for the decision rule to go to phase III (HR<sub>go</sub>)
* total number of events for phase II (d<sub>2</sub>)
* total expected number of events for one phase III (d<sub>3</sub>)
* total expected number of events in the program (d)
* probability to go to phase III (p<sub>go</sub>)
* probability of a successful program (sProg)
* probability of a successful program with small effect (sProg1)
* probability of a successful program with medium effect (sProg2)
* probability of a successful program with large effect (sProg3)
* costs for phase II (K2)
* costs for phase III (K3)

and further input parameters.


#### References

Dunnett, C. W. (1955). A multiple comparison procedure for comparing several treatments with a control. <i>Journal of the American Statistical Association</i> 50(272), 1096-1121.

Horn, M., and Vollandt, R. (1998). Sample sizes for comparisons of k treatments with a control based on different definitions of the power. <i>Biometrical Journal</i> 40(5), 589-612.

Magirr, D., Jaki, T., and Whitehead, J. (2012). A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection. <i>Biometrika</i> 99(2), 494-501.

Schoenfeld, D. (1981). The asymptotic properties of nonparametric tests for comparing survival distributions. <i>Biometrika</i> 68(1), 316-319.
